Oneview Healthcare (ASX:ONE) has announced it has formed a 5-year R&D partnership with The University of Oxford and Oxford University Hospital NHS Foundation Trust.
The partnership will continue research and development on a clinical pathways product.
The catalyst for the R&D tie-up was the success of an earlier pilot into digital pathways for prostate cancer to improve patient outcomes and deliver cost efficiencies to health systems
The new research will focus on expanding the technology to include full commercial deployment at Oxford and expansion of scope into other types of cancer.
Oneview Healthcare (ASX:ONE) was trading around 1.98 % higher this morning at $2.06.